Clinical Trial

Renal Cancer Detection With Liquid Biopsy

Study acronym: GaGnostic

Recruiting

Record status

This record was last updated January 30, 2024 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.

Summary

Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are shared by other benign lesions in the kidney, such as angiomyolipomas, oncocytomas, or PEComa.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2021-09-28; most recent amendment 2024-01-27.

Trial Details

NCT Number	NCT05060783
Lead Sponsor	Zealand University Hospital Collaborators: Lund University, Elypta
Conditions	Renal Cancer, Oncocytoma
Enrollment	200 participants
Start Date	2021-07-01
Primary Completion	2025-07-01 (estimated)
Study Completion	2027-07-01 (estimated)
Updated on ClinicalTrials.gov	2024-01-30